AR and prostate neoplasm: While a variety of AR transgenic mouse models have been developed for assessing AR action in prostate oncogenesis in the past decades7, these models all used the mouse probasin (PB) promoter to induce transgenic AR expression and only showed minor pathological changes and failed to develop prostate tumor lesions as observed in human prostate cancer8,9.